Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases

Journal of Molecular Diagnostics

Volumn 8, Issue 3, 2006, Pages 299-304

  Horn, Thomas ^a   Kremer, Marcus ^a   Dechow, Tobias ^a   Pfeifer, Walther M ^a,d   Geist, Birgit ^a   Perker, Michael ^b   Duyster, Justus ^a   Quintanilla Martinez, Leticia ^c   Fend, Falko ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Haematology Clinic   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; JANUS KINASE 2; PARAFFIN;

ADULT; AGED; ALLELE; ARTICLE; BONE MARROW BIOPSY; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; ERYTHROCYTOSIS; FEMALE; GENE MUTATION; GENE SEQUENCE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; THROMBOCYTHEMIA; THROMBOCYTOSIS;

EID: 33745990527     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.2353/jmoldx.2006.050128     Document Type: Article

References (18)

1. Vardiman J, Brunning R, Harris NL: Chronic myeloproliferative diseases. World Health Organization Classification of Tumours. Tumours of Haematopoietic and Lymphoid Tissues. Edited by Jaffe E, Harris NL, Stein H, Vardiman J. Lyon, IARC Press, 2001, pp 15-44
2. Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302
3. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM. Curtin N, Scott MA, Erber WN, Green AR: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061
4. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassillou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR: Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005, 366:1945-1953
5. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148
6. Kaushansky K: On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood 2005, 105:4187-4190
7. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790
8. Levine RL. Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397
9. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A: European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005, 90:1128-1132
10. Greer CE, Peterson SL, Kiviat NB, Manos MM: PCR amplification from paraffin-embedded tissues. Effects of fixative and fixation time. Am J Clin Pathol 1991, 95:117-124
11. Kremer M, Spitzer M, Mandl-Weber S, Stecker K, Schmidt B, Hofler H, Quintanilla-Martinez L, Fend F: Discordant bone marrow involvement in diffuse large B-cell lymphoma: comparative molecular analysis reveals a heterogeneous group of disorders. Lab Invest 2003, 83:107-114
12. Fend F, Bock O, Kremer M, Specht K, Quintanilla-Martinez L: Ancillary techniques in bone marrow pathology: molecular diagnostics on bone marrow trephine biopsies. Virchows Arch 2005, 447:909-919
13. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa J-PJ: JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005, 106:3370-3373
14. Jones AV, Kreil S. Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ. Grand FH, White H, Zoi C. Loukopoulos D, Terpos E, Vervessou E-C, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NCP: Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005, 106:2162-2168
15. Levine RL, Loriaux M, Huntly BJP, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E, Gattermann N, Armstrong S, Look AT, Griffin JD, Bernard OA, Heinrich MC, Gilliland DG, Druker B, Deininger MWN: The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005, 106:3377-3379
16. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, Zhao ZJ: Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005, 280:22788-22792
17. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A: The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 2005, 106: 1207-1209
18. Bock O, Büsche G. Koop C, Schröter S, Buhr T. and Kreipe H: Detection of the single hotspot mutation in the JH2 pseudokinase domain of janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders. J Mol Diagn 2006, 8:170-177